title: Cervical cancer: is vaccination necessary in India?
abstract: In India, cervical cancer is the most common woman-related cancer, followed by breast cancer. The rate of cervical cancer in India is fourth worldwide. Two vaccines, Gardasil and Cervarix, both targeting HPV-16 and 18 which account for 70% of invasive cervical carcinomas, are licensed in the United States and numerous countries worldwide. Both vaccine formulations have shown excellent efficacy with minimal toxicity in active female population but numerous questions arise in vaccinating like cost effectiveness, lack of proven efficacy against other HPV strains, social acceptance of HPV vaccination and other ethical issues. The main objective of this study is to emphasis the advantages and disadvantages of the vaccination in India.
authors.affiliation: Bharathiar University, Coimbatore, Tamilnadu, India. seema_farhath@yahoo.com
authors.forename: Seema
authors.initials: S
authors.lastname: Farhath
authors.forename: P P
authors.initials: PP
authors.lastname: Vijaya
authors.forename: P
authors.initials: P
authors.lastname: Mumtaj
mesh_terms: D005260:Female; D006801:Humans; D007194:India; D027383:Papillomaviridae / Q000145:classification / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000191:economics / Q000627:therapeutic use*; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000191:economics / Q000517:prevention & control* / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines